New Visikol HISTO-M Publication: Development of a 3D Organoid System Using iPSCs to Model Idiopathic Autism

It is always rewarding to see how our clients, customers and collaborators are using our products and assay services to develop novel therapeutics and to address complex research questions. In this publication from researchers at the Hussman Institute for Autism and the University of Maryland, they leveraged Visikol HISTO-M to characterize iPSC-derived organoids in their entirety using high content imaging.

Our Visikol HISTO-M reagents allow researchers to characterize these models in 3D such that their entire three-dimensional structure can be interrogated. These researchers were using organoid neuronal models to develop an in vitro approach for studying idiopathic Autism.

Autism spectrum disorder affects millions of people around the globe and affects their ability to socially interact with others, and many other domains of common human behavior. With limited knowledge about the disorder and a wide range of variations, only a small number of treatments have been developed and thus this group is working to develop novel models for evaluating Autism and potential treatment approaches.

2020-08-18T15:16:28-05:00Tags: , , |

Share This Page, Choose Your Platform!